GB1575977A - Solid choline salicylate compositions - Google Patents
Solid choline salicylate compositions Download PDFInfo
- Publication number
- GB1575977A GB1575977A GB2512/77A GB251277A GB1575977A GB 1575977 A GB1575977 A GB 1575977A GB 2512/77 A GB2512/77 A GB 2512/77A GB 251277 A GB251277 A GB 251277A GB 1575977 A GB1575977 A GB 1575977A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- salicylate
- carboxy
- solid
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 title claims abstract description 64
- 229960002688 choline salicylate Drugs 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims description 93
- 239000007787 solid Substances 0.000 title description 20
- 229910052751 metal Inorganic materials 0.000 claims abstract description 30
- 239000002184 metal Substances 0.000 claims abstract description 30
- 229920013820 alkyl cellulose Polymers 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 34
- 239000003826 tablet Substances 0.000 claims description 28
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 23
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 23
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 22
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 22
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 22
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 21
- 229960001860 salicylate Drugs 0.000 claims description 21
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 18
- 239000008247 solid mixture Substances 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 239000003085 diluting agent Substances 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 13
- 239000000829 suppository Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- -1 carboxy propyl Chemical group 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000007909 solid dosage form Substances 0.000 claims description 8
- 229910052782 aluminium Inorganic materials 0.000 claims description 6
- 239000004411 aluminium Substances 0.000 claims description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052797 bismuth Inorganic materials 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229920003064 carboxyethyl cellulose Polymers 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 abstract description 7
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 12
- 229940072082 magnesium salicylate Drugs 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- GQSZLMMXKNYCTP-UHFFFAOYSA-K aluminum;2-carboxyphenolate Chemical compound [Al+3].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O GQSZLMMXKNYCTP-UHFFFAOYSA-K 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229920001429 chelating resin Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910001415 sodium ion Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 229910001414 potassium ion Inorganic materials 0.000 description 3
- 150000003873 salicylate salts Chemical class 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- REKWPXFKNZERAA-UHFFFAOYSA-K bismuth;2-carboxyphenolate Chemical compound [Bi+3].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O REKWPXFKNZERAA-UHFFFAOYSA-K 0.000 description 2
- AVVIDTZRJBSXML-UHFFFAOYSA-L calcium;2-carboxyphenolate;dihydrate Chemical compound O.O.[Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O AVVIDTZRJBSXML-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 239000007892 solid unit dosage form Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229910001451 bismuth ion Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- DQKGOGJIOHUEGK-UHFFFAOYSA-M hydron;2-hydroxyethyl(trimethyl)azanium;carbonate Chemical compound OC([O-])=O.C[N+](C)(C)CCO DQKGOGJIOHUEGK-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
- A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65111076A | 1976-01-21 | 1976-01-21 | |
| US05/705,056 US4067974A (en) | 1976-01-21 | 1976-07-14 | Stabilized solid form choline salicylate compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1575977A true GB1575977A (en) | 1980-10-01 |
Family
ID=27096002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9401/79A Expired GB1575978A (en) | 1976-01-21 | 1977-01-21 | Solid choline salicylate compositions |
| GB2512/77A Expired GB1575977A (en) | 1976-01-21 | 1977-01-21 | Solid choline salicylate compositions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9401/79A Expired GB1575978A (en) | 1976-01-21 | 1977-01-21 | Solid choline salicylate compositions |
Country Status (23)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043168A (en) * | 1990-04-26 | 1991-08-27 | Sidmak Laboratories, Inc. | Solid choline magnesium salicylate composition and method of preparing same |
| US5217965A (en) * | 1991-06-17 | 1993-06-08 | Euroceltique, S.A. | Stabilized solid dosage forms of choline metal carboxymethylcellulose salicylate compositions |
| USD843660S1 (en) | 2017-11-27 | 2019-03-19 | Mary Kay Inc. | Cosmetic compact |
| USD850006S1 (en) | 2017-11-27 | 2019-05-28 | Mary Kay Inc. | Cosmetic compact |
| USD863685S1 (en) | 2017-11-27 | 2019-10-15 | Mary Kay Inc. | Cosmetic compact |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3347744A (en) * | 1963-10-25 | 1967-10-17 | Smith Kline French Lab | Magnesium hydroxide suspensions |
| US3297529A (en) * | 1964-11-25 | 1967-01-10 | Sutton Lab Inc | Magnesium sulfate stabilized choline salicylate |
| US3326760A (en) * | 1966-05-17 | 1967-06-20 | Synergistics Inc | Choline salicylate polygalacturonate therapy |
| US3759980A (en) * | 1969-05-26 | 1973-09-18 | Stockton Chemicals Inc | Salicylates |
-
1976
- 1976-09-08 CA CA260,766A patent/CA1070299A/en not_active Expired
- 1976-11-25 IL IL50992A patent/IL50992A/xx unknown
- 1976-12-06 NZ NZ182810A patent/NZ182810A/xx unknown
- 1976-12-07 GR GR52348A patent/GR62110B/el unknown
- 1976-12-22 AR AR265966A patent/AR217249A1/es active
- 1976-12-23 SE SE7614538A patent/SE418799B/xx not_active IP Right Cessation
- 1976-12-30 FI FI763741A patent/FI56770C/fi not_active IP Right Cessation
- 1976-12-30 ES ES454712A patent/ES454712A1/es not_active Expired
-
1977
- 1977-01-10 CH CH25977A patent/CH635816A5/de not_active IP Right Cessation
- 1977-01-12 YU YU69/77A patent/YU40159B/xx unknown
- 1977-01-14 RO RO7789053A patent/RO71764A/ro unknown
- 1977-01-15 DE DE2760284A patent/DE2760284C2/de not_active Expired - Lifetime
- 1977-01-15 DE DE19772701553 patent/DE2701553A1/de active Granted
- 1977-01-18 AU AU21419/77A patent/AU511510B2/en not_active Expired
- 1977-01-19 EG EG36/77A patent/EG12511A/xx active
- 1977-01-19 NL NLAANVRAGE7700514,A patent/NL183821C/xx not_active IP Right Cessation
- 1977-01-20 NO NO770172A patent/NO145295C/no unknown
- 1977-01-20 DK DK021677A patent/DK149804C/da not_active IP Right Cessation
- 1977-01-20 HU HU77MU577A patent/HU175973B/hu unknown
- 1977-01-20 FR FR7701571A patent/FR2338705A1/fr active Granted
- 1977-01-21 GB GB9401/79A patent/GB1575978A/en not_active Expired
- 1977-01-21 MX MX775373U patent/MX5920E/es unknown
- 1977-01-21 GB GB2512/77A patent/GB1575977A/en not_active Expired
- 1977-01-21 JP JP52006319A patent/JPS6051449B2/ja not_active Expired
- 1977-01-21 DD DD7700197041A patent/DD128908A5/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2735903B2 (ja) | イブプロフエン沸騰製剤 | |
| KR940002659B1 (ko) | 치료제 조성물의 제조방법 | |
| US5348745A (en) | Aqueous granulation solution and a method of tablet granulation | |
| EP0351353B1 (en) | Anti-inflammatory pharmaceutical composition with an ibuprofen base, with elimination, in solution, of the bitter taste, burning in the throat and intestinal toxicity | |
| KR20010071765A (ko) | 제약학적 레보타이록신 제제 | |
| US4067974A (en) | Stabilized solid form choline salicylate compositions | |
| US4666919A (en) | Stabilized pharmaceutical composition containing an isocarbostyril derivative | |
| GB1575977A (en) | Solid choline salicylate compositions | |
| US20050171070A1 (en) | Stable salts of o-acetylsalicylic acid containing basic amino acids II | |
| US4428951A (en) | Long acting pharmaceutical composition | |
| US8293272B2 (en) | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts | |
| EP0505180A1 (en) | High-content ibuprofen lysinate pharmaceutical formulation | |
| JP2594395B2 (ja) | アズレンスルホン酸ナトリウムの安定化法および製剤 | |
| CA2523079C (en) | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts | |
| US3326760A (en) | Choline salicylate polygalacturonate therapy | |
| IE45201B1 (en) | Solid choline salicylate compositions | |
| RU2192248C2 (ru) | Препарат "антигриппин" | |
| GB2061111A (en) | Long acting pharmaceutical composition | |
| US4338311A (en) | Hydrophilic choline salicylate formulation | |
| RU2248205C1 (ru) | Лекарственное средство в виде желатиновой капсулы | |
| RU2160105C1 (ru) | Противовирусное средство и способ его получения | |
| SU1748822A1 (ru) | Способ получени твердой лекарственной формы противовоспалительного средства | |
| RU2155032C1 (ru) | Способ получения лекарственной формы противовоспалительного симптоматического действия | |
| RU2276982C2 (ru) | Средство, обладающее противовоспалительным, анальгетическим, жаропонижающим действием в форме таблетки | |
| EA042077B1 (ru) | Сухая порошкообразная фармацевтическая композиция для ингаляции, содержащая тиреоидный гормон |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PE20 | Patent expired after termination of 20 years |
Effective date: 19970120 |